Scribe Therapeutics priced an upsized initial public offering to raise about $129 million, extending a strong biotech IPO run and giving the CRISPR-focused developer fresh funding for early clinical and platform work. The company priced 8.6 million shares at $15 each, and began trading on Nasdaq under the ticker SCTX. Scribe’s lead in vivo gene editing program is aimed at lipid regulation and cardiometabolic disease, with near-term use of proceeds for an ongoing Phase 1 study and additional assets targeting cardiovascular pathways. For the market, Scribe’s reception highlights continued investor demand for in vivo gene editing outside rare disease, even as companies balance cash runway with early-stage execution risk.